Literature DB >> 15030524

Antibodies to TSH-receptor in thyroid autoimmune disease interact with monoclonal antibodies whose epitopes are broadly distributed on the receptor.

W B Minich1, C Lenzner, N G Morgenthaler.   

Abstract

The hyperthyroidism of Graves' disease (GD) is caused by TSH-receptor (TSH-R) stimulating autoantibodies (TSAb), leading to overproduction of thyroid hormones. We present evidence for TSAb interaction with three distinct regions of the TSH-R, one in immediate vicinity of the carboxy terminal serpentine. Three murine monoclonal antibodies (MoAbs 28.1, A9 and 31.7) directed to amino acids 36-40, 147-228 and 382-415 were labelled and tested for their binding to human recombinant TSH-R on solid phase. All MoAbs bound to TSH-R with a K(d) of 8-12 nm and showed no competition among themselves. We tested 114 sera from euthyroid controls, 118 TBII positive sera from patients with GD (containing TSAb confirmed by bioassays), 16 TBII positive sera from patients with autoimmune thyroid disease (AIT), who were hypothyroid and had TSH blocking antibodies (TBAb), and 20 patients with AIT, who were hypothyroid but negative for all TRAb. Mid-regional MoAb A9 tracer achieved the highest sensitivity in the GD group (72.0%), whereas C-terminal MoAb 31.7 found most sera positive in the AIT group (87.5%). Surprisingly, the N-terminal MoAb 28.1 had the lowest sensitivity in the GD (10.4%) and AIT group (43.8%). Using a mixture of all three tracer MoAbs did not increase the sensitivity in the GD or AIT group, compared to the best single MoAb alone. Median inhibition of MoAb A9 was significantly (P < 0.001) higher than inhibition of MoAbs 28.1 or 31.7 in the group of GD patients but not in other groups. Almost all patient sera with positive reactivity in the MoAb tracer assays had TBII values in the higher range. However, there were many highly TBII positive sera, which did not show a displacement of the MoAb tracers. We conclude that, contrary to some reports, the binding of TSAb and TBAb to the TSH-R is not restricted to distinct and distant epitopes. The middle part of the TSH-R seems to be more relevant for TSAb binding than the N-terminal part, while a proportion of TSAb autoantibodies also binds to a C-terminal epitope of the TSH-R. The method described here is a TSH independent competitive assay for the detection of TSH-R autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15030524      PMCID: PMC1808985          DOI: 10.1111/j.1365-2249.2004.02417.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

Review 1.  Graves' disease.

Authors:  A P Weetman
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

Review 2.  The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies.

Authors:  B Rapoport; G D Chazenbalk; J C Jaume; S M McLachlan
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

3.  Epitope analysis of the human thyrotropin (TSH) receptor using monoclonal antibodies.

Authors:  Y Oda; J Sanders; M Evans; A Kiddie; A Munkley; C James; T Richards; J Wills; J Furmaniak; B R Smith
Journal:  Thyroid       Date:  2000-12       Impact factor: 6.568

4.  A luminescent bioassay for thyroid blocking antibodies.

Authors:  N J Jordan; C Rinderle; J Ashfield; N G Morgenthaler; J Lazarus; M Ludgate; C Evans
Journal:  Clin Endocrinol (Oxf)       Date:  2001-03       Impact factor: 3.478

5.  Glycosylated ectodomain of the human thyrotropin receptor induces antibodies capable of reacting with multiple blocking antibody epitopes.

Authors:  G S Seetharamaiah; J S Dallas; B S Prabhakar
Journal:  Autoimmunity       Date:  1999       Impact factor: 2.815

6.  The interaction of TSH receptor autoantibodies with 125I-labelled TSH receptor.

Authors:  J Sanders; Y Oda; S Roberts; A Kiddie; T Richards; J Bolton; V McGrath; S Walters; D Jaskólski; J Furmaniak; B R Smith
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

7.  Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation.

Authors:  M Schott; J Feldkamp; C Bathan; R Fritzen; W A Scherbaum; J Seissler
Journal:  Horm Metab Res       Date:  2000-10       Impact factor: 2.936

8.  Identification of an important thyrotrophin binding site on the human thyrotrophin receptor using monoclonal antibodies.

Authors:  P S Shepherd; C R Da Costa; J C Cridland; K S Gilmore; A P Johnstone
Journal:  Mol Cell Endocrinol       Date:  1999-03-25       Impact factor: 4.102

9.  Differences in the levels of TSH-binding inhibitor immunoglobulins in goitrous and agoitrous autoimmune thyroiditis after twelve months of L-thyroxine therapy.

Authors:  D H Khoo; P H Eng; S C Ho; A C Fok
Journal:  Clin Endocrinol (Oxf)       Date:  1999-07       Impact factor: 3.478

10.  Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease.

Authors:  S Costagliola; N G Morgenthaler; R Hoermann; K Badenhoop; J Struck; D Freitag; S Poertl; W Weglöhner; J M Hollidt; B Quadbeck; J E Dumont; P M Schumm-Draeger; A Bergmann; K Mann; G Vassart; K H Usadel
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

View more
  4 in total

Review 1.  Delineating the autoimmune mechanisms in Graves' disease.

Authors:  Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

2.  Characterization of thyrotropin receptor antibody-induced signaling cascades.

Authors:  Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Endocrinology       Date:  2008-08-21       Impact factor: 4.736

Review 3.  Blocking type TSH receptor antibodies.

Authors:  Jadwiga Furmaniak; Jane Sanders; Bernard Rees Smith
Journal:  Auto Immun Highlights       Date:  2012-03-21

4.  Natural autoantibodies to the gonadotropin-releasing hormone receptor in polycystic ovarian syndrome.

Authors:  Lisa-Marie Sattler; Hanna A Schniewind; Waldemar B Minich; Christoph W Haudum; Petra Niklowitz; Julia Münzker; Gábor L Kovács; Thomas Reinehr; Barbara Obermayer-Pietsch; Lutz Schomburg
Journal:  PLoS One       Date:  2021-04-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.